Anelixis Therapeutics LLC, formed in 2013 as a for-profit subsidiary of the nonprofit ALS Therapy Development Institute (ALS TDI), has begun enrolling the phase I dose-escalation study of AT-1501, a humanized anti-CD40 ligand (CD40L) monoclonal antibody. The single-site study at Massachusetts General Hospital (MGH) is examining safety and pharmacokinetics in six cohorts of healthy volunteers and one of individuals with amyotrophic lateral sclerosis (ALS). Top-line data are expected at the end of March, according to Steven Perrin, founder, president, CEO and sole employee of the Cambridge, Mass.-based company.